Ximelagatran versus warfarin for prophylaxis of venous thromboembolism in major orthopedic surgery
systematic review of randomized controlled trials
Keywords:
Venous thrombosis, Pulmonary embolism, Orthopedics, Primary prevention, Meta-analysisAbstract
BACKGROUND: Ximelagatran has been recently studied for prophylaxis in surgical orthopedic cases. PURPOSE: We proposed to establish whether in- terventions involving ximelagatran, as compared with warfarin, would increase thromboembolic prophylaxis in patients undergoing major ortho- pedic knee surgery. DATA SOURCE: Studies with random assignment were identified by an electronic search of the medical literature up to 2006. Data were double- entered into the Review Manager software, version 4.2.5. DATA SYNTHESIS: We included three well conducted clinical trials involving 4,914 participants. Sub-groups with two dosages of ximelagatran (24 mg and 36 mg, b.i.d.), were defined. Ximelagatran showed significantly lower frequency of total venous thromboembolism (VTE) than warfarin, but only with the 36-mg dosage (risk relative, RR: 0.72; 95% confidence interval, CI: 0.64-0.81; p < 0.00001). For the 24-mg subgroup, total VTE frequency was similar (RR: 0.86; 95% CI: 0.73-1.01; p = 0.06). No significant differences were shown with either ximelagatran dosage for deep vein thrombosis (DVT), pulmonary embolism, any bleeding or severe bleeding. At the end of the treatment, alanine aminotransferase (ALT) elevation was less frequent in the 24-mg ximelagatran sub-group (RR: 0.33; 95% CI: 0.12-0.91; p = 0.03], but during the follow-up period, the ALT elevation rate was greater in the 36-mg ximelagatran group (RR: 6.97; 95% CI: 1.26-38.50; p = 0.03]. CONCLUSIONS: Ximelagatran appears to be more effective than warfarin when used in higher dosages (36 mg b.i.d.), but at the expense of increased frequency of ALT elevation during the follow-up period.
Downloads
References
Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. J Vasc Br. 2002;1(2):133-70. Available from: http://www.jvascbr.com.br/02-01-02/02-01-02-133/02-01-02- 133.pdf. Accessed in 2006 (Out 18).
Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Anti- thrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S-400S.
Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393. Lancet. 1996;347(9002):635-9.
Eriksson BI, Ekman S, Lindbratt S, et al. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am. 1997;79(3):326-33.
Eriksson BI, Wille-Jorgensen P, Kalebo P, et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replace- ment. N Engl J Med. 1997;337(19):1329-35.
Gustafsson D, Elg M. The pharmacodynamics and pharmaco- kinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109(Suppl 1):S9-15.
Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res. 2003;109(Suppl 1):S23-9.
Zufferey P, Laporte S, Molliex S, Auboyer C, Mismetti P. Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration. J Thromb Haemost. 2005;3(5):1104-7.
Cohen AT, Hirst C, Sherrill B, Holmes P, Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg. 2005;92(11):1335-44.
Alderson P, Green S. Huggins JPT. Cochrane Reviewers’ Hand- book 4.2.2. Assessment of study quality. Section 4. In: Alderson P, Green S. Huggins JPT, editors. The Cochrane Library [updated December 2003]. Chichester: John Wiley & Ltd.; 2004.
Juni P, Witschi A, Bloch R, Egger M. The hazards of scor- ing the quality of clinical trials for meta-analysis. JAMA. 1999;282(11):1054-60.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349(18):1703-12.
Colwell CW Jr., Berkowitz SD, Lieberman JR, et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87(10):2169-77.
Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med. 2002;137(8):648-55.
Van Aken H, Bode C, Darius H, et al. Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001;7(3):195-204.
Hirsh J, O’Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453-63.
Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001;16(3):293-300.
Heit JA. Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacement. Thromb Res. 2001;101(1):V163-73.
Eriksson BI, Arfwidsson AC, Frison L, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replace- ment: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost. 2002;87(2):231-7.
Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the ME- THRO II randomised trial. Lancet. 2002;360(9344):1441-7.
Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibi- tor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89(2):288-96.
Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003;1(12):2490-6.
Colwell CW Jr., Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxa- parin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003;1(10):2119-30.
Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrilla- tion: a randomized trial. JAMA. 2005;293(6):690-8.
Olsson SB; Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691-8.
Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H; THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-21.
Sander GE, Giles TD. Ximelagatran: light at the end of the tunnel or the next tunnel? Am J Geriatr Cardiol. 2004;13(4):221-4.
Gulseth MP. Ximelagatran: an orally active direct thrombin inhibitor. Am J Health Syst Pharm. 2005;62(14):1451-67.
Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous throm- boembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet. 2002;359(9319):1721-6.
Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboem- bolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002;162(13):1465-71.
